Adjuvant Therapy for High-Risk Soft Tissue Sarcoma in the Adult

被引:14
作者
Gronchi, Alessandro [1 ]
Casali, Paolo G. [2 ]
机构
[1] Fdn IRCCS Ist Nazl Tumori, Dept Surg, Sarcoma Serv, Milan, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Dept Canc Med, Adult Mesenchymal Tumor Med Oncol Unit, Milan, Italy
关键词
Sarcoma; Soft tissue sarcoma; Chemotherapy; Adjuvant; GASTROINTESTINAL STROMAL TUMOR; PHASE-II TRIAL; RADIATION-THERAPY; IMATINIB MESYLATE; SURGICAL MARGINS; PREOPERATIVE RADIATION; MYXOID LIPOSARCOMAS; PROGNOSTIC-FACTORS; MTOR INHIBITION; CLINICAL-TRIAL;
D O I
10.1007/s11864-013-0243-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Adult-type soft tissue sarcomas (STS) are curable in roughly one half of cases. Surgery is the treatment mainstay in patients with localized STS and should be performed in centers that have specific expertise with the disease. Radiation therapy complements surgery in several cases, improving the local control. The value of adjuvant chemotherapy is still debated. There is some evidence, however, backing the notion that adjuvant chemotherapy may add to the systemic control of the disease, and thereby overall survival, in the subgroup of patients with high-risk STS. These patients are those with a high-grade, large, and deep tumor. Unfortunately, benefit is apparent when merging all data generated by several trials performed throughout decades, but it was not confirmed by the largest trials, including one that was recently reported. A confounding factor for large clinical trials is that STS are a family of 50-plus different histological subtypes. It is difficult to perform studies that focus on each of them separately, and subgroup analyses suffer from many limitations. Indeed, some histological types are more sensitive to standard chemotherapy and other are less. Furthermore, some histologies are specifically sensitive to some agents that may be completely inactive in others. A prospective, randomized trial is underway to compare standard neoadjuvant chemotherapy in high-risk STS versus a neoadjuvant regimen that is tailored to different histologies. Some rare histological subtypes (alveolar soft part sarcoma, clear cell sarcoma, extraskeletal myxoid chondrosarcoma, solitary fibrous tumor) have shown promising sensitivity to molecular target agents in the metastatic setting, but the value of these therapies in the adjuvant one has not been studied yet. It is probable that in the future the biological background of the different soft tissue sarcoma subtypes will guide the selection of therapies as well as the setting to deliver them.
引用
收藏
页码:415 / 424
页数:10
相关论文
共 50 条
  • [41] Adult soft tissue sarcoma
    Mann, GB
    Lewis, JJ
    Brennan, MF
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1999, 69 (05): : 336 - 343
  • [42] Preoperative accelerated radiotherapy combined with chemotherapy in a defined cohort of patients with high risk soft tissue sarcoma: a Scandinavian Sarcoma Group study
    Hall, Kirsten Sundby
    Bruland, Oyvind S.
    Bjerkehagen, Bodil
    Lidbrink, Elisabet
    Jebsen, Nina
    Hagberg, Hans
    Papworth, Karin
    Hagberg, Oskar
    Trovik, Clement
    Bauer, Henrik
    Eriksson, Mikael
    [J]. CLINICAL SARCOMA RESEARCH, 2020, 10 (01)
  • [43] Current state of neoadjuvant therapy of soft tissue sarcoma
    Lehnhardt, M.
    Schmitt, T.
    Bischof, M.
    Daigeler, A.
    Egerer, G.
    [J]. CHIRURG, 2011, 82 (11): : 995 - 1000
  • [44] A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma
    Thomas Schmitt
    Burkhard Lehner
    Bernd Kasper
    Marc Bischof
    Falk Roeder
    Sascha Dietrich
    Antonia Dimitrakopoulou-Strauss
    Ludwig G Strauss
    Gunhild Mechtersheimer
    Patrick Wuchter
    Anthony D Ho
    Gerlinde Egerer
    [J]. BMC Cancer, 11
  • [45] Revision of: a phase II study on the neo-adjuvant combination of pazopanib and radiotherapy in patients with high-risk, localized soft tissue sarcoma
    van Meekeren, Milan
    Bovee, Judith V. M. G.
    van Coevorden, Frits
    van Houdt, Winan
    Schrage, Yvonne
    Koenen, Anne Miek
    Miah, Aisha B.
    Zaidi, Shane
    Hayes, Andrew J.
    Thway, Khin
    Krol, Stijn
    Fiocco, Marta
    Gelderblom, Hans
    Steeghs, Neeltje
    Haas, Rick L.
    [J]. ACTA ONCOLOGICA, 2021, 60 (12) : 1557 - 1564
  • [46] Management of adult soft-tissue sarcoma of the extremities and trunk
    Abraham, John A.
    Baldini, Elizabeth H.
    Butrynski, James E.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (02) : 233 - 248
  • [47] The impact of CT-based adipose tissue distribution and sarcopenia on treatment outcomes in patients with high-risk soft tissue sarcoma
    Luc M. Berclaz
    Dorit Di Gioia
    Michael Völkl
    Vindi Jurinovic
    Alexander Klein
    Hans Roland Dürr
    Thomas Knösel
    Bianca Teodorescu
    Stefan Enßle
    Michaela Rippl
    Michael von Bergwelt-Baildon
    Wolfgang G. Kunz
    Lars H. Lindner
    Anton Burkhard-Meier
    [J]. BMC Cancer, 25 (1)
  • [48] Non-rhabdomyosarcoma soft-tissue sarcoma
    Milgrom, Sarah A.
    Million, Lynn
    Mandeville, Henry
    Safwat, Akmal
    Ermoian, Ralph P.
    Terezakis, Stephanie
    [J]. PEDIATRIC BLOOD & CANCER, 2021, 68
  • [49] Radiation Therapy for Soft Tissue Sarcoma Indications and Controversies for Neoadjuvant Therapy, Adjuvant Therapy, Intraoperative Radiation Therapy, and Brachytherapy
    Larrier, Nicole A.
    Czito, Brian G.
    Kirsch, David G.
    [J]. SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 25 (04) : 841 - +
  • [50] Tolerance of tissue transfers to adjuvant radiation therapy in primary soft tissue sarcoma of the extremity
    Spierer, MM
    Alektiar, KM
    Zelefsky, MJ
    Brennan, MF
    Cordiero, PG
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (04): : 1112 - 1116